Share Name Share Symbol Market Type Share ISIN Share Description
Cello Group LSE:CLL London Ordinary Share GB00B0310763 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 134.00p 132.00p 136.00p - - - 0 05:30:11
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Media 169.3 5.8 4.1 32.8 140.31

Cello Share Discussion Threads

Showing 976 to 998 of 1000 messages
Chat Pages: 40  39  38  37  36  35  34  33  32  31  30  29  Older
DateSubjectAuthorDiscuss
19/9/2018
09:35
Cenkos; Cello Health has released positive interim results in-line with forecasts, indicating FY18E will be another year of steady growth. The Cello Health business continues to make mid-single digit underlying GP progress, driven by positive market dynamics and a high penetration of the global healthcare community. Cello Signal’s digital expertise meanwhile are increasingly being leveraged into the healthcare space, giving rise to potential future margin appreciation. We expect the typical H2 weighting results to recur in FY18E in meeting our forecast +10% adj EPS growth. n H1/18A results indicate another steady year: The group delivered steady progress in H1/18A, with gross profit (GP) growth of 3.9% to £51.0m and 9.3% growth in headline operating profit (HOP) to £5.3m, at a 10.4% (H1/17A: 10.0%) margin. Growth was tempered by weaker av. dollar conversion rates ($1.38 vs $1.26), where 30% of group GP is now earned in the US. We expect this to reverse in H2/18E, based on USD’s current strengthening. H1/17A comparatives did not include the acquisition of Advantage Healthcare (acquired July 17) and only 5 months of Defined Health (acquired Feb 17). LFL constant currency GP growth was 3.0% for the period. n Cello Health – the engine room of growth: The Cello Health business continues to be the source of the group’s momentum. It delivered strong GP growth of 11.7% to £31.4m, or 7.2% on a LFL CC basis. HOP increased by 16.1% to £5.7m at a slightly improved margin of 18.0% (H1:17.4%). Both acquisitions continued to trade as expected and have been added to this month by the bolt-on acquisition of Firstlight Communications, for a minimal consideration. Firstlight produces communications programmes for pharma and med-tech clients in the UK and overseas. Cello Health continues to make operational and financial progress through the recruitment of clinically-led professionals, the establishment of new US hubs and a more collaborative culture under one brand. It is also benefitting from positive market dynamics, where global healthcare R&D spend is increasing at c5% pa, with an ongoing trend by clients (particularly smaller biotech clients) to outsource some aspects of the commercial decision making process when bringing a drug to launch. n Cello Signal increasingly servicing healthcare clients: Cello Signal delivered lower GP for the period of £19.4m (-2.0% YoY or -2.9% on a LFL CC basis) owing to loss of income from the downsizing of unprofitable US West Coast activities in FY17A. This did however contribute to a 3.9% rise in HOP to £1.2m, at an improved margin of 6.4% (H1/17A: 6.0%). We expect the seasonally stronger H2 delivery in Signal to recur this year and lead to FY18E margins of 10%+. The development of Signal’s offer for healthcare clients is gaining considerable traction, with Signal’s non-healthcare orientated staff buying into the commercial opportunity following several new wins in the space. Pulsar, particularly, is demonstrating how Signal’s digital skillsets can be applied in the healthcare space, with the social media analytics tool being used for pitches, in combination with Cello Health. n Cleaner set of numbers expected this year: We note today’s results include reductions in certain below the line items compared with previous results (eg restructuring provisions, start-up losses, VAT exceptionals), narrowing the gap between statutory and underlying reporting. We also expect the full year results to mirror this trend in line with our FY18E forecasts. n Forecasts unchanged: The group traditionally exhibits a modest H2 weighting to results (particularly Cello Signal) and we note that 49% (H1/17A: 48%) of FY18E GP and 42% (H1/17A: 41%) of HOP has already been delivered in these results. We therefore consider this to signify in-line trading, and thus leave our forecasts unchanged, save for an update to share count. We expect the group to deliver a +10% uplift in adj EPS and +3% uplift in DPS this year. n Valuation – yet to account fully for the recurring nature of income: Cello currently trades on an FY18E P/E of 15.5x, or 9.3x on an EV/EBITDA basis. We consider these multiples to fail to take account of the degree of habitually recurring income Cello generates based on multi-year Master Service Agreements (MSAs) with its clients. These, combined with Cello’s penetration into 24/25 of the top big pharma players and an increasing number of high growth biotechs, gives the group a diverse and recurring annuity-like income. This quality of earnings benefits a valuation multiple more akin to larger listed healthcare services peers such as UDG Healthcare (FY18E P/E: 18.8x) and those competitors domiciled in the US (typically 20x+ P/E’s).
davebowler
18/9/2018
11:31
lets see what tomorrow brings!
eentweedrie
16/2/2018
12:33
tipped somewhere?
qs99
16/2/2018
11:39
OK, nice retrace!
qs99
30/1/2018
15:03
any views on recent drop?
qs99
30/1/2018
12:41
graph not looking too clever?
qs99
09/11/2017
10:02
bit of a trace back going on here, any clues?
qs99
18/7/2017
11:31
FinnCap; Cello has announced the acquisition of Advantage Healthcare Inc. for an initial consideration of $1.5m cash. Deferred consideration of up to $3.0m will also be paid dependent on financial performance to June 2021. Advantage (founded 20 years ago) provides critical analysis and insights in biopharmaceuticals supporting new products and business development. It will complement Cello Health's existing capabilities in consulting, market research and science-based communications and will add further depth to it's ability to work from the early stages of drug development and across the life cycle. Advantage reported sales of $4.5m in 2016 and operating profit of $0.3m. We will reassess our forecasts with tomorrows trading statement and note that given our forecast of £5m net cash at December 2017 there is scope for further bolt-ons that strengthen the offering and growth prospects.
davebowler
03/7/2017
10:04
and now rebounding firmly it would seem....DYOR
qs99
07/6/2017
07:20
Agreed, I believe there is some portfolio balancing occurring to reduce exposure to surprise outcomes in the forthcoming election.
mike-green
06/6/2017
10:12
not surprised to see some material profit taking...
qs99
04/5/2017
12:10
check out the web-site, may have that on it....looks like profit taking, well done all who have ridden the wave, froth coming off now placing, await next deals IMO...I'll monitor now and work out next entry position, hoping it may be below £1.20 but buyers may return before then....GLA
qs99
27/3/2017
13:31
Please can you help Who are the major share holders? Thanks bb123
bb123
22/3/2017
11:56
hxxps://www.research-tree.com/blogs/news/cello-group-profits-ahead-of-expectations
lampran
09/2/2017
16:26
great strength, hope a few have been following this, c.15% up in a week...
qs99
08/2/2017
09:52
Continued good moves....a great story really IMO given fund raise, more than required, implying more deals (+use of debt) in future, tech focus in new broker notes, share price already 10%+ above placing price as well received....more to come IMO as reckon from this share price rise, there are a few who are buying into story....DYOR and gla
qs99
08/2/2017
08:22
STILL in demand it would appear. latest broker notes have all been very positive, interesting to see one is talking about CLL being a tech play as well now with its capabilities....
qs99
06/2/2017
12:32
OK if a tech=backed model, what p/e or EV/EBITDA ratio will the market ascribe to CLL? Presume much higher than now, hence the re-rate? DYOR
qs99
06/2/2017
12:24
thanks for that. also decent yield IMO
qs99
06/2/2017
12:06
FinnCap; Post the placing, Cello has net cash and, with an acquisition, has signalled its intent to invest for growth now that the VAT issue is firmly behind it. We continue to believe Pulsar, its social media tool, is in the share price for free, but also increasingly that Cello has developed a widening range of technologies that are performing well and support good profit growth potential. Cello is moving away from an ‘hours utilised and billed' type model towards a technology-backed model, a more valuable proposition.
davebowler
01/2/2017
11:39
The oversubscribed placing underpins the share price and there is all to play for in 2017
zipstuck
01/2/2017
09:27
well that was unexpected but a nice surprise....any thoughts on this very quiet board?
qs99
19/1/2017
09:36
Price: 100.0p Target Price: 132.0p finncap.com Cello has confirmed the Group delivered an encouraging trading performance in 2016 and 2017 begins with good momentum from existing and new clients. Most importantly for our buy case, there has been an ‘excellent performance’ from Cello’s growing suite of software-enabled products. We make no changes to our forecasts and continue to believe the share price significantly undervalues the technologies Cello has developed, most notably Pulsar its social media analytics tool which we believe is in the price for free.
davebowler
Chat Pages: 40  39  38  37  36  35  34  33  32  31  30  29  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180920 05:55:21